MedTrace Logo

3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

NCT00064051 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-08-02

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them more sensitive to the drug.

PURPOSE: This phase II trial is studying how well giving gemcitabine together with 3-AP works in treating patients with unresectable or metastatic pancreatic cancer.

Conditions

Interventions

DRUG

gemcitabine hydrochloride

DRUG

triapine

Sponsors & Collaborators

  • Vion Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Mario Sznol, MD · Vion Pharmaceuticals

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2006-08-31
Completion
2008-08-31

Countries

  • United States
  • Belgium
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00064051 on ClinicalTrials.gov